Literature DB >> 19888317

Epilepsy: Generic substitution: are antiepileptic drugs different?

Carl W Bazil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19888317     DOI： 10.1038/nrneurol.2009.162

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  7 in total

1.  Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy.

Authors:  K Liow; G L Barkley; J R Pollard; C L Harden; C W Bazil
Journal:  Neurology       Date:  2007-04-17       Impact factor: 9.910

2.  What's the problem with generic antiepileptic drugs?: a call to action.

Authors:  Michel J Berg
Journal:  Neurology       Date:  2007-04-17       Impact factor: 9.910

3.  Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.

Authors:  Woodie M Zachry; Quynhchau D Doan; Jerry D Clewell; Brien J Smith
Journal:  Epilepsia       Date:  2008-06-26       Impact factor: 5.864

Review 4.  Bioequivalence of antiepileptic drugs: how close is close enough?

Authors:  Barry E Gidal
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

5.  Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.

Authors:  J LeLorier; M S Duh; P E Paradis; P Lefebvre; J Weiner; R Manjunath; O Sheehy
Journal:  Neurology       Date:  2008-05-27       Impact factor: 9.910

6.  The risks and costs of multiple-generic substitution of topiramate.

Authors:  M S Duh; P E Paradis; D Latrémouille-Viau; P E Greenberg; S P Lee; M B Durkin; G J Wan; M F T Rupnow; J LeLorier
Journal:  Neurology       Date:  2009-06-16       Impact factor: 9.910

7.  Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.

Authors:  Frederick Andermann; Mei Sheng Duh; Antoine Gosselin; Pierre Emmanuel Paradis
Journal:  Epilepsia       Date:  2007-03       Impact factor: 5.864
  7 in total
  1 in total

1.  [Change from original preparations to generics. A case example with oxcarbazepine].

Authors:  G Hagemann; J Zinke; M Fuchs; O W Witte
Journal:  Nervenarzt       Date:  2010-12       Impact factor: 1.214
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.